Project Grant R43AI197314
Award Date 8/13/26
Completion Date 1/31/27
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Blacksburg, VA, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Biotherapeutics, Inc. $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop oral first-in-class small-molecule therapeutics targeting a novel immunometabolic pathway for multiple sclerosis treatment. Biotherapeutics, Inc., a clinical-stage biotechnology company headquartered in Blacksburg, Virginia, will conduct Phase I research validating the safety, efficacy, and...
- The National Institute of Allergy and Infectious Diseases awarded Vanderbilt University Medical Center $481,250 on April 1, 2026, to develop and test inhibitors of the reverse transsulfuration pathway as a novel treatment for Helicobacter pylori infection under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research evaluates aminooxyacetic acid (AOAA) and propargylglycine (PAG)—compounds initially developed to inhibit mammalian reverse transsulfuration pathway...
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $225,846 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antivirulence inhibitors targeting bacterial type IV pili as a strategy against antibiotic resistance. The project advances small-molecule therapeutics that interfere with type IV pilus biogenesis and function in gram-negative pathogens. Rather than killing bacteria...
- The National Institute of Allergy and Infectious Diseases awarded Applied Biotechnology Institute Inc. $299,936 on August 14, 2026, under the Allergy and Infectious Diseases Research program to develop heat-stable forms of adalimumab produced in maize for treatment of inflammatory bowel disease. Applied Biotechnology Institute Inc. will produce large quantities of adalimumab, a TNF-targeting therapeutic antibody, using a proprietary recombinant maize expression system. The company will...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services National Institutes of Health, awarded $437,541 to Virginia Polytechnic Institute & State University on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antisense therapeutics targeting Clostridioides difficile infection. The research focuses on designing antisense oligomers, including peptide nucleic acids, to suppress...
- The National Institute of Allergy and Infectious Diseases awarded Virtici LLC $306,500 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a first-in-class, orally administered probiotic therapy for treatment and prevention of Klebsiella pneumoniae gastrointestinal colonization, transmission, and infection. The award is a Project Grant with assistance type classification. K. pneumoniae causes pneumonia, urinary tract infections, bloodstream...
- The National Institute of Allergy and Infectious Diseases awarded Partillion Bioscience Corp $306,865 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanovial-based technologies for accelerated monoclonal antibody discovery and characterization. Partillion will engineer novel nanovial formulations to enable streptavidin-antigen complexes as detection agents, increasing the multiplexing capacity of single-cell antibody screening assays. The...
- The National Institute of Allergy and Infectious Diseases awarded Virtici LLC $300,222 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to commercialize VTC-L35, an orally administered, immune-modulating probiotic therapy for rheumatoid arthritis. The project targets long-term disease remission in rheumatoid arthritis patients by developing an oral immunotherapeutic that regulates auto-antigen-specific regulatory T cells and B cells to produce...
- The National Institute of Allergy and Infectious Diseases awarded Prodigy Biotech, Inc. $314,363 on September 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel immunoglobulin Y (IGY) therapeutic targeting Candida albicans and candidalysin in alcohol-associated hepatitis. Prodigy will generate high-titer IGY antibodies derived from hyperimmune chicken eggs against C. albicans and candidalysin, then evaluate their neutralization capabilities in...
- The National Institute of Allergy and Infectious Diseases awarded Astero Erado Inc. $306,449 on August 11, 2026, to develop a novel therapeutic for bullous pemphigoid, an autoimmune disease characterized by severe blistering at the dermal-epidermal junction. The award funds work under the Allergy and Infectious Diseases Research program (CFDA 93.855). Astero Erado is developing an engineered antibody-based therapeutic called SELDEG designed to selectively target and deplete pathogenic...